Top ▲
Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
TNFR1 (tumor necrosis factor receptor 1 / TNFRSF1A) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
TNFR2 (tumor necrosis factor receptor 2 / TNFRSF1B) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
lymphotoxin β receptor / TNFRSF3 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
OX40 / TNFRSF4 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
CD40 / TNFRSF5 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
Fas / TNFRSF6 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
decoy receptor 3 / TNFRSF6B C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
CD27 / TNFRSF7 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
CD30 / TNFRSF8 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
4-1BB / TNFRSF9 C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
DR4 (death receptor 4 / TNFRSF10A) C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
DR5 (death receptor 5 / TNFRSF10B) C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
decoy receptor 1 / TNFRSF10C C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
decoy receptor 2 / TNFRSF10D C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
RANK (receptor activator of NF-kappa B / TNFRSF11A) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
OPG (osteoprotegerin / TNFRSF11B) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
DR3 (death receptor 3 / TNFRSF25) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
TWEAK receptor / TNFRSF12A C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
TACI / TNFRSF13B C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
BAFF-R (BAFF receptor / TNFRSF13C) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
HVEM (herpes virus entry mediator / TNFRSF14) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
nerve growth factor receptor / TNFRSF16 C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
BCMA (B cell maturation antigen / TNFRSF17) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
GITR (glucocorticoid-induced TNF receptor / TNFRSF18) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
TAJ (toxicity and JNK inducer / TNFRSF19) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
RELT / TNFRSF19L C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
DR6 (death receptor 6 / TNFRSF21) C Show summary »« Hide summary More detailed page
|
|||||||||||||||||||||||||||
TNFRSF22 C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
TNFRSF23 C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
ectodysplasin A2 isoform receptor / TNFRS27 C Show summary »« Hide summary
|
|||||||||||||||||||||||||||
ectodysplasin 1, anhidrotic receptor C Show summary »« Hide summary
|
* Key recommended reading is highlighted with an asterisk
Aggarwal BB. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol, 3 (9): 745-56. [PMID:12949498]
Ashkenazi A. (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer, 2 (6): 420-30. [PMID:12189384]
* Blaser H, Dostert C, Mak TW, Brenner D. (2016) TNF and ROS Crosstalk in Inflammation. Trends Cell Biol, 26 (4): 249-261. [PMID:26791157]
* Croft M, Siegel RM. (2017) Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol, 13 (4): 217-233. [PMID:28275260]
Huang EJ, Reichardt LF. (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci, 24: 677-736. [PMID:11520916]
* Kalliolias GD, Ivashkiv LB. (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol, 12 (1): 49-62. [PMID:26656660]
Mahmood Z, Shukla Y. (2010) Death receptors: targets for cancer therapy. Exp Cell Res, 316 (6): 887-99. [PMID:20026107]
* Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. (2016) Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther, 159: 110-9. [PMID:26808166]
Rickert RC, Jellusova J, Miletic AV. (2011) Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev, 244 (1): 115-33. [PMID:22017435]
Tansey MG, Szymkowski DE. (2009) The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today, 14 (23-24): 1082-8. [PMID:19837186]
* von Karstedt S, Montinaro A, Walczak H. (2017) Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer, 17 (6): 352-366. [PMID:28536452]
1. Bremer E. (2013) Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol, 2013: 371854. [PMID:23840967]
2. Brenner D, Blaser H, Mak TW. (2015) Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol, 15 (6): 362-74. [PMID:26008591]
3. Dhillon S. (2024) Aponermin: First Approval. Drugs, 84 (4): 459-466. [PMID:38441805]
4. Hanson GJ, Vuletich JL, Bedell LJ, Bono CP, Howard SC, Welpy JW, Woulfe SL, Zacheis ML. (1996) Design of MHC class II (DR4) ligands using conformationally restricted imino acids at p3 and p5. Bioorg Med Chem Lett, 6 (16): 1931–1936.
5. Jeon YH, Lee JY, Kim S. (2012) Chemical modulators working at pharmacological interface of target proteins. Bioorg Med Chem, 20 (6): 1893-901. [PMID:22227462]
6. Massa SM, Xie Y, Yang T, Harrington AW, Kim ML, Yoon SO, Kraemer R, Moore LA, Hempstead BL, Longo FM. (2006) Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J Neurosci, 26 (20): 5288-300. [PMID:16707781]
7. Sedger LM, McDermott MF. (2014) TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev, 25 (4): 453-72. [PMID:25169849]
8. Song Y, Margolles-Clark E, Bayer A, Buchwald P. (2014) Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction. Br J Pharmacol, 171 (21): 4955-69. [PMID:24930776]
9. Wang EC. (2012) On death receptor 3 and its ligands…. Immunology, 137 (1): 114-6. [PMID:22612445]
10. Webb GJ, Hirschfield GM, Lane PJ. (2016) OX40, OX40L and Autoimmunity: a Comprehensive Review. Clin Rev Allergy Immunol, 50 (3): 312-32. [PMID:26215166]
11. Yan M, Wang LC, Hymowitz SG, Schilbach S, Lee J, Goddard A, de Vos AM, Gao WQ, Dixit VM. (2000) Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science, 290 (5491): 523-7. [PMID:11039935]
12. Zhou T, Ichikawa K, Kimberley RP, Koopman WJ. (2001) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof. Patent number: WO2001083560. Assignee: Uab Research Foundation. Priority date: 02/05/2000. Publication date: 08/11/2001.
David MacEwan |
Database page citation (select format):
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors. Br J Pharmacol. 180 Suppl 2:S241-288.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
TNFRSF1A is preferentially activated by the shed form of TNF ligand, whereas the membrane-bound form of TNF serves to activate TNFRSF1A and TNFRSF1B equally. The neurotrophins nerve growth factor (NGF (NGF, P01138)), brain-derived neurotrophic factor (BDNF (BDNF, P23560)), neurotrophin-3 (NTF3, P20783) (NTF3) and neurotrophin-4 (NTF4, P34130) (NTF4) are structurally unrelated to the TNF ligand superfamily but exert some of their actions through the “low affinity nerve growth factor receptor” (NGFR (TNFRSF16)) as well as through the TRK family of receptor tyrosine kinases. The endogenous ligands for EDAR and EDA2R are, respectively, the membrane (Q92838[1-391]) and secreted (Q92838[160-391]) isoforms of Ectodysplasin-A (EDA, Q92838).